K⁺ channels in the heart: new insights and therapeutic implications

References

• Noble D. The surprising heart: a review of recent progress in cardiac electrophysiology. J. Physiol. (Lond.)353, 1–50 (1984).
   Google Scholar
• Salkoff L, Jegla T. Surfing the DNA databases for K+ channels nets yet more diversity. Neuron15, 489–492 (1995).
   Google Scholar
• Jan LY, Jan YN. Cloned potassium channels from eukaryotes and prokaryotes. Annu. Rev. Neurosci.20, 91–123 (1997).
   PubMed Web of Science ®Google Scholar
• Gouaux E, MacKinnon R. Principles of selective ion transport in channels and pumps. Science310, 1461–1465 (2005).
   PubMed Web of Science ®Google Scholar
• Long SB, Tao X, Campbell EB, MacKinnon R. Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. Nature450, 376–382 (2007).
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Newton-Cheh C. Genetic determinants of sudden cardiac death. Circulation118, 1854–1863 (2008).
   Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114, e257–e354 (2006).
   PubMed Web of Science ®Google Scholar
• Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol. Rev.85, 1205–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc. Res.62, 9–33 (2004).
   PubMed Web of Science ®Google Scholar
• Nattel S. New ideas about atrial fibrillation 50 years on. Nature415, 219–226 (2002).
   PubMed Web of Science ®Google Scholar
• Baruscotti M, Robinson RB. Electrophysiology and pacemaker function of the developing sinoatrial node. Am. J. Physiol. Heart Circ. Physiol.293, H2613–H2623 (2007).
   Google Scholar
• Baron A, van Bever L, Monnier D, Roatti A, Baertschi AJ. A novel K(ATP) current in cultured neonatal rat atrial appendage cardiomyocytes. Circ. Res.85, 707–715 (1999).
   Google Scholar
• Flagg TP, Kurata HT, Masia R et al. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ. Res.103, 1458–1465 (2008).
   PubMed Web of Science ®Google Scholar
• Dixon JE, Shi W, Wang HS et al. Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res.79, 659–668 (1996).
   PubMed Web of Science ®Google Scholar
• An WF, Bowlby MR, Betty M et al. Modulation of A-type potassium channels by a family of calcium sensors. Nature403, 553–556 (2000).
   PubMed Web of Science ®Google Scholar
• Patel SP, Parai R, Parai R, Campbell DL. Regulation of Kv4.3 voltage-dependent gating kinetics by KChIP2 isoforms. J. Physiol.557, 19–41 (2004).
   PubMed Web of Science ®Google Scholar
• Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, Schrader LA. Structure and function of Kv4-family transient potassium channels. Physiol. Rev.84, 803–833 (2004).
   PubMed Web of Science ®Google Scholar
• Rettig J, Heinemann SH, Wunder F et al. Inactivation properties of voltage-gated K+ channels altered by presence of β-subunit. Nature369, 289–294 (1994).
   PubMed Web of Science ®Google Scholar
• London B, Wang DW, Hill JA, Bennett PB. The transient outward current in mice lacking the potassium channel gene Kv1.4. J. Physiol.509(Pt 1), 171–182 (1998).
   PubMed Web of Science ®Google Scholar
• Gaborit N, Le BS, Szuts V et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol.582, 675–693 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ. Res.73, 1061–1076 (1993).
   PubMed Web of Science ®Google Scholar
• Martens JR, Kwak YG, Tamkun MM. Modulation of Kv channel α/β subunit interactions. Trends Cardiovasc. Med.9, 253–258 (1999).
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Gomez R, Delpon E. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin. Investig. Drugs18, 399–416 (2009).
   PubMed Web of Science ®Google Scholar
• Pond AL, Scheve BK, Benedict AT et al. Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional I(Kr) channels. J. Biol. Chem.275, 5997–6006 (2000).
   PubMedGoogle Scholar
• Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell97, 175–187 (1999).
   PubMed Web of Science ®Google Scholar
• Chen H, Kim LA, Rajan S, Xu S, Goldstein SA. Charybdotoxin binding in the I(Ks) pore demonstrates two MinK subunits in each channel complex. Neuron40, 15–23 (2003).
   PubMedGoogle Scholar
• Sanguinetti MC, Curran ME, Zou A et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature384, 80–83 (1996).
   PubMed Web of Science ®Google Scholar
• Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature384, 78–80 (1996).
   PubMed Web of Science ®Google Scholar
• Schram G, Pourrier M, Melnyk P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ. Res.90, 939–950 (2002).
   PubMed Web of Science ®Google Scholar
• Lopatin AN, Nichols CG. Inward rectifiers in the heart: an update on I(K1). J. Mol. Cell. Cardiol.33, 625–638 (2001).
   PubMed Web of Science ®Google Scholar
• Zaritsky JJ, Redell JB, Tempel BL, Schwarz TL. The consequences of disrupting cardiac inwardly rectifying K(+) current (I(K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J. Physiol533, 697–710 (2001).
   PubMed Web of Science ®Google Scholar
• Liu GX, Derst C, Schlichthorl G et al. Comparison of cloned Kir2 channels with native inward rectifier K+ channels from guinea-pig cardiomyocytes. J. Physiol.532, 115–126 (2001).
   PubMed Web of Science ®Google Scholar
• Noma A, Trautwein W. Relaxation of the ACh-induced potassium current in the rabbit sinoatrial node cell. Pflügers Archiv.377, 193–200 (1978).
   PubMed Web of Science ®Google Scholar
• Dascal N, Schreibmayer W, Lim NF et al. Atrial G protein-activated K+ channel: expression cloning and molecular properties. Proc. Natl Acad. Sci. USA90, 10235–10239 (1993).
   PubMed Web of Science ®Google Scholar
• Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature364, 802–806 (1993).
   PubMed Web of Science ®Google Scholar
• Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, Clapham DE. The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins. Nature374, 135–141 (1995).
   PubMed Web of Science ®Google Scholar
• Wickman K, Nemec J, Gendler SJ, Clapham DE. Abnormal heart rate regulation in Girk4 knockout mice. Neuron20, 103–114 (1998).
   PubMed Web of Science ®Google Scholar
• Zingman LV, Alekseev AE, Hodgson-Zingman DM, Terzic A. ATP-sensitive potassium channels: metabolic sensing and cardioprotection. J. Appl. Physiol.103, 1888–1893 (2007).
   PubMed Web of Science ®Google Scholar
• Yutzey KE, Robbins J. Principles of genetic murine models for cardiac disease. Circulation115, 792–799 (2007).
   Google Scholar
• Fiset C, Clark RB, Larsen TS, Giles WR. A rapidly activating sustained K+ current modulates repolarization and excitation–contraction coupling in adult mouse ventricle. J. Physiol.504(Pt 3), 557–563 (1997).
   PubMed Web of Science ®Google Scholar
• Brunet S, Aimond F, Li H et al. Heterogeneous expression of repolarizing, voltage-gated K+ currents in adult mouse ventricles. J. Physiol.559, 103–120 (2004).
   PubMed Web of Science ®Google Scholar
• Nerbonne JM. Studying cardiac arrhythmias in the mouse – a reasonable model for probing mechanisms? Trends Cardiovasc. Med.14, 83–93 (2004).
   PubMed Web of Science ®Google Scholar
• Heginbotham L, Lu Z, Abramson T, MacKinnon R. Mutations in the K+ channel signature sequence. Biophys. J.66, 1061–1067 (1994).
   PubMed Web of Science ®Google Scholar
• Aldrich RW. Fifty years of inactivation. Nature411, 643–644 (2001).
   PubMed Web of Science ®Google Scholar
• Bezanilla F. How membrane proteins sense voltage. Nat. Rev. Mol. Cell Biol.9, 323–332 (2008).
   PubMed Web of Science ®Google Scholar
• MacKinnon R. Potassium channels and the atomic basis of selective ion conduction (Nobel lecture). Angew. Chem. Int. Ed. Engl.43, 4265–4277 (2004).
   PubMed Web of Science ®Google Scholar
• Tombola F, Pathak MM, Isacoff EY. How does voltage open an ion channel? Annu. Rev. Cell Dev. Biol.22, 23–52 (2006).
   PubMed Web of Science ®Google Scholar
• Nichols CG, Makhina EN, Pearson WL, Sha Q, Lopatin AN. Inward rectification and implications for cardiac excitability. Circ. Res.78, 1–7 (1996).
   PubMedGoogle Scholar
• Corey S, Clapham DE. Identification of native atrial G-protein-regulated inwardly rectifying K+ (GIRK4) channel homomultimers. J. Biol. Chem.273, 27499–27504 (1998).
   PubMed Web of Science ®Google Scholar
• Fleischmann BK, Duan Y, Fan Y et al. Differential subunit composition of the G protein-activated inward-rectifier potassium channel during cardiac development. J. Clin. Invest.114, 994–1001 (2004).
   PubMed Web of Science ®Google Scholar
• Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol.61, 337–362 (1999).
   PubMed Web of Science ®Google Scholar
• Rodrigo GC, Standen NB. ATP-sensitive potassium channels. Curr. Pharm. Des.11, 1915–1940 (2005).
   PubMed Web of Science ®Google Scholar
• Alekseev AE, Hodgson DM, Karger AB, Park S, Zingman LV, Terzic A. ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart. J. Mol. Cell. Cardiol.38, 895–905 (2005).
   PubMedGoogle Scholar
• Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am. J. Physiol. Renal Physiol.279, F793–F801 (2000).
   PubMed Web of Science ®Google Scholar
• Putzke C, Wemhoner K, Sachse FB et al. The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc. Res.75, 59–68 (2007).
   PubMed Web of Science ®Google Scholar
• Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ. Res.74, 1071–1096 (1994).
   PubMed Web of Science ®Google Scholar
• Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ. Res.68, 1501–1526 (1991).
   PubMed Web of Science ®Google Scholar
• Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res.42, 477–489 (1999).
   PubMed Web of Science ®Google Scholar
• Nygren A, Fiset C, Firek L et al. Mathematical model of an adult human atrial cell: the role of K+ currents in repolarization. Circ. Res.82, 63–81 (1998).
   PubMed Web of Science ®Google Scholar
• January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ. Res.64, 977–990 (1989).
   PubMed Web of Science ®Google Scholar
• The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation84, 1831–1851 (1991).
   PubMed Web of Science ®Google Scholar
• Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca(2+) release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ. Res.87, 774–780 (2000).
   PubMed Web of Science ®Google Scholar
• Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med.14, 61–66 (2004).
   PubMed Web of Science ®Google Scholar
• Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation101, 194–199 (2000).
   PubMed Web of Science ®Google Scholar
• The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur. Heart J.12, 1112–1131 (1991).
   PubMed Web of Science ®Google Scholar
• Colatsky TJ, Argentieri TM. Potassiun channel blockers as antiarrhythmic drugs. Drug Dev. Res.33, 235–249 (1994).
   Google Scholar
• Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov.2, 439–447 (2003).
   PubMed Web of Science ®Google Scholar
• Nattel S, Carlsson L. Innovative approaches to antiarrhythmic drug therapy. Nat. Rev. Drug Discov.5, 1034–1049 (2006).
   PubMed Web of Science ®Google Scholar
• Nattel S, Maguy A, Le BS, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev.87, 425–456 (2007).
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med.321, 406–412 (1989).
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med.327, 227–233 (1992).
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet348, 7–12 (1996).
   PubMed Web of Science ®Google Scholar
• Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial investigators. Lancet349, 667–674 (1997).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J. Clin. Invest.115, 2018–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Huang L, Bitner-Glindzicz M, Tranebjaerg L, Tinker A. A spectrum of functional effects for disease causing mutations in the Jervell and Lange–Nielsen syndrome. Cardiovasc. Res.51, 670–680 (2001).
   PubMed Web of Science ®Google Scholar
• Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA97, 12329–12333 (2000).
   PubMed Web of Science ®Google Scholar
• Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation105, 1247–1253 (2002).
   PubMed Web of Science ®Google Scholar
• Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation103, 2004–2013 (2001).
   PubMed Web of Science ®Google Scholar
• Hondeghem LM. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur. J. Pharmacol.584, 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ. Res.72, 75–83 (1993).
   PubMed Web of Science ®Google Scholar
• Nakashima H, Gerlach U, Schmidt D, Nattel S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc. Res.61, 705–714 (2004).
   Google Scholar
• Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science299, 251–254 (2003).
   PubMed Web of Science ®Google Scholar
• Xia M, Jin Q, Bendahhou S et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem. Biophys. Res. Commun.332, 1012–1019 (2005).
   PubMed Web of Science ®Google Scholar
• Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol.16, 394–396 (2005).
   PubMed Web of Science ®Google Scholar
• Yang Y, Xia M, Jin Q et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet.75, 899–905 (2004).
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Van G, I, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347, 1834–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med.352, 1861–1872 (2005).
   PubMed Web of Science ®Google Scholar
• Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation92, 1954–1968 (1995).
   PubMed Web of Science ®Google Scholar
• Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ. Res.81, 512–525 (1997).
   PubMed Web of Science ®Google Scholar
• Gaspo R, Bosch RF, Bou-Abboud E, Nattel S. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ. Res.81, 1045–1052 (1997).
   PubMed Web of Science ®Google Scholar
• Van Wagoner DR, Pond AL, McCarthy PM, Trimmer JS, Nerbonne JM. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res.80, 772–781 (1997).
   PubMed Web of Science ®Google Scholar
• Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ. Res.84, 776–784 (1999).
   PubMed Web of Science ®Google Scholar
• Dobrev D, Graf E, Wettwer E et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation104, 2551–2557 (2001).
   Google Scholar
• Dobrev D, Friedrich A, Voigt N et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation112, 3697–3706 (2005).
   PubMed Web of Science ®Google Scholar
• Xiao L, Xiao J, Luo X, Lin H, Wang Z, Nattel S. Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. Circulation118, 983–992 (2008).
   PubMed Web of Science ®Google Scholar
• Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am. Heart J.157, 243–252 (2009).
   PubMed Web of Science ®Google Scholar
• Norgaard BL, Wachtell K, Christensen PD et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J.137, 1062–1069 (1999).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med.341, 857–865 (1999).
   PubMed Web of Science ®Google Scholar
• Roukoz H, Saliba W. Dofetilide: a new class III antiarrhythmic agent. Expert Rev. Cardiovasc. Ther.5, 9–19 (2007).
   PubMedGoogle Scholar
• Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br. J. Clin. Pharmacol.50, 247–253 (2000).
   Google Scholar
• Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current antiarrhythmic drugs, investigational agents, and innovative approaches. Europace10, 647–665 (2008).
   PubMed Web of Science ®Google Scholar
• Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol.41, 191–202 (2003).
   PubMed Web of Science ®Google Scholar
• Guillemare E, Marion A, Nisato D, Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J. Cardiovasc. Pharmacol.36, 802–805 (2000).
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357, 987–999 (2007).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van EM et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358, 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol.54, 1089–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm5, 1304–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a Phase 3, randomized, placebo-controlled trial. Circulation117, 1518–1525 (2008).
   PubMed Web of Science ®Google Scholar
• Eldstrom J, Wang Z, Xu H et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol. Pharmacol.72, 1522–1534 (2007).
   PubMed Web of Science ®Google Scholar
• Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs16, 519–532 (2007).
   PubMed Web of Science ®Google Scholar
• Crijns HJ, Van GI, Walfridsson H et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm3, 1321–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Blaauw Y, Gogelein H, Tieleman RG, van HA, Schotten U, Allessie MA. ‘Early’ class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation110, 1717–1724 (2004).
   PubMed Web of Science ®Google Scholar
• DE Vos CB, Nieuwlaat R, Crijns HJ et al. Autonomic trigger patterns and antiarrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur. Heart J.29, 632–639 (2008).
   PubMed Web of Science ®Google Scholar
• Coumel P, Attuel P, Lavallee J, Flammang D. The atrial arrhythmia syndrome of vagal origin. Arch. Mal. Coeur Vaiss.71, 645–656 (1978).
   PubMedGoogle Scholar
• Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation105, 2753–2759 (2002).
   PubMed Web of Science ®Google Scholar
• Sharifov OF, Fedorov VV, Beloshapko GG, Glukhov AV, Yushmanova AV, Rosenshtraukh LV. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J. Am. Coll. Cardiol.43, 483–490 (2004).
   PubMed Web of Science ®Google Scholar
• Pappone C, Santinelli V, Manguso F et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation109, 327–334 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol. Rev.50, 723–757 (1998).
   PubMed Web of Science ®Google Scholar
• Voigt N, Maguy A, Yeh YH et al. Changes in IK,ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc. Res.77, 35–43 (2008).
   PubMed Web of Science ®Google Scholar
• Voigt N, Friedrich A, Bock M et al. Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation. Cardiovasc. Res.74, 426–437 (2007).
   Google Scholar
• Leaney JL, Dekker LV, Tinker A. Regulation of a G-protein gated inwardly rectifying potassium channel by a Ca2+-independent protein kinase C. J. Physiol. (Lond.)534, 367–379 (2001).
   Google Scholar
• Kitamura H, Yokoyama M, Akita H, Matsushita K, Kurachi Y, Yamada M. Tertiapin potently and selectively blocks muscarinic K(+) channels in rabbit cardiac myocytes. J. Pharmacol. Exp. Ther.293, 196–205 (2000).
   Google Scholar
• Drici MD, Diochot S, Terrenoire C, Romey G, Lazdunski M. The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine-induced atrioventricular blocks. Br. J. Pharmacol.131, 569–577 (2000).
   Google Scholar
• Jin W, Lu Z. Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry38, 14286–14293 (1999).
   PubMedGoogle Scholar
• Kanjhan R, Coulson EJ, Adams DJ, Bellingham MC. Tertiapin-Q blocks recombinant and native large conductance K+ channels in a use-dependent manner. J. Pharmacol. Exp. Ther.314, 1353–1361 (2005).
   PubMedGoogle Scholar
• Hashimoto N, Yamashita T, Tsuruzoe N. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide. J. Cardiovasc. Pharmacol.51, 162–169 (2008).
   Google Scholar
• Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu. Rev. Pharmacol. Toxicol.33, 597–637 (1993).
   PubMed Web of Science ®Google Scholar
• Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and β-cell K(ATP) channels. Diabetes47, 1412–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Gribble FM, Ashcroft FM. Differential sensitivity of β-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia42, 845–848 (1999).
   PubMed Web of Science ®Google Scholar
• Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human β-cell sulphonylurea receptor 1. Diabetes51, 2789–2795 (2002).
   PubMed Web of Science ®Google Scholar
• Zingman LV, Hodgson DM, Bast PH et al. Kir6.2 is required for adaptation to stress. Proc. Natl Acad. Sci. USA99, 13278–13283 (2002).
   PubMed Web of Science ®Google Scholar
• Liu XK, Yamada S, Kane GC et al. Genetic disruption of Kir6.2, the pore-forming subunit of ATP-sensitive K+ channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes53(Suppl. 3), S165–S168 (2004).
   Google Scholar
• Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev.83, 1113–1151 (2003).
   PubMed Web of Science ®Google Scholar
• O’Rourke B. Mitochondrial ion channels. Annu. Rev. Physiol69, 19–49 (2007).
   PubMed Web of Science ®Google Scholar
• Chi L, Uprichard AC, Lucchesi BR. Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death. J. Cardiovasc. Pharmacol.15, 452–464 (1990).
   PubMed Web of Science ®Google Scholar
• Kerr MJ, Wilson R, Shanks RG. Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J. Cardiovasc. Pharmacol.7, 875–883 (1985).
   PubMed Web of Science ®Google Scholar
• Balana B, Dobrev D, Wettwer E, Christ T, Knaut M, Ravens U. Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation. J. Mol. Cell. Cardiol.35, 1399–1405 (2003).
   Web of Science ®Google Scholar
• Arking DE, Pfeufer A, Post W et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat. Genet.38, 644–651 (2006).
   PubMed Web of Science ®Google Scholar
• Pfeufer A, Sanna S, Arking DE et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat. Genet.41, 407–414 (2009).
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Eijgelsheim M, Rice KM et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat. Genet.41, 399–406 (2009).
   PubMed Web of Science ®Google Scholar
• Chang KC, Barth AS, Sasano T et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc. Natl Acad. Sci. USA105, 4477–4482 (2008).
   Google Scholar
• Gudbjartsson DF, Arnar DO, Helgadottir A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature448, 353–357 (2007).
   PubMed Web of Science ®Google Scholar
• Kaab S, Darbar D, van NC et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur. Heart J.30, 813–819 (2009).
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Holm H, Gretarsdottir S et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat. Genet.41, 876–878 (2009).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Rice KM, Arking DE et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat. Genet.41, 879–881 (2009).
   PubMed Web of Science ®Google Scholar